Corpus ID: 70553400

Efficient deposition and sustained lung concentrations of NVA237 after inhalation via the Breezhaler® device in man

@article{Schaud2012EfficientDA,
  title={Efficient deposition and sustained lung concentrations of NVA237 after inhalation via the Breezhaler{\textregistered} device in man},
  author={R. S{\'e}chaud and Manish Sudershan and S. Perry and Hisanori Hara and A. Drollmann and R. Karan and L. D. Scala and S. Biswal and Beverley E Patterson and G. Kaiser},
  journal={European Respiratory Journal},
  year={2012},
  volume={40},
  pages={4839}
}
Introduction This study in healthy volunteers (HVs) was designed to investigate the bioavailability of inhaled NVA237 (glycopyrronium bromide-GP) delivered via the Breezhaler® device and to investigate the contributions of pulmonary and gastrointestinal (GI) absorption to systemic exposure. GI absorption was blocked with oral activated charcoal (AC) to study the pharmacokinetics (PK) of the NVA237 absorption via the lung. Methods In Part 1, NVA237 400 µg was administered orally to 10 HVs with… Expand
Lung Delivery of Indacaterol and Mometasone Furoate Following Inhalation of QMF149 in Healthy Volunteers
TLDR
Data from this study and comparison with inhalation of indacaterol via the BRZ device suggest that the latter was more efficient than the TH device regarding lung delivery of indACaterol. Expand
Pharmacokinetics of mometasone furoate delivered via two dry powder inhalers.
BACKGROUND QMF149 is an inhaled fixed-dose combination of indacaterol acetate and mometasone furoate (MF) delivered via Breezhaler®, under development for once-daily treatment of asthma. MF deliveredExpand
Determination of the pharmacokinetics of glycopyrronium in the lung using a population pharmacokinetic modelling approach.
TLDR
The slow absorption from the lungs, together with the rapid elimination from the systemic circulation, could explain how once-daily glycopyrronium provides sustained bronchodilatation with a low incidence of adverse effects in patients with chronic obstructive pulmonary disease. Expand
Gaining an insight into the importance of each inhalation manoeuvre parameter using altered patients’ inhalation profiles
Abstract The aerodynamic particle size distribution (APSD) and dose emission characteristics of indacaterol Breezhaler have been measured using ex-vivo methodology and altering original COPDExpand
Profile of inhaled glycopyrronium bromide as monotherapy and in fixed-dose combination with indacaterol maleate for the treatment of COPD
Chronic obstructive pulmonary disease (COPD) is a major cause of morbidity and mortality. The cornerstone of pharmacological treatment for COPD is bronchodilation. Inhaled glycopyrronium bromide is aExpand
Once-daily glycopyrronium via the Breezhaler® device for the treatment of COPD: pharmacological and clinical profile
TLDR
Glycopyrronium is an inhaled once-daily long-acting muscarinic antagonist recently approved for the maintenance treatment of patients with COPD that has been shown to provide rapid and sustained improvements in lung function, dyspnea, health status, exercise endurance and exacerbation risk and an acceptable safety and tolerability profile. Expand
Área de asma de SEPAR, Área de enfermería de SEPAR, Departamento de asma ALAT
TLDR
Desde hace años, diversos organismos (sociedades, grupos e industria farmacéutica), han promovido la formación de dichos profesionales en los diferentes aspectos relacionados with la terapia inhalada en el ámbito científico en lengua española. Expand